Orion Pharma Limited
|
Nature of business
|
The Company owns and operates a modern
pharmaceuticals factory and produces and sells
pharmaceuticals drugs and medicine.
|
|
Reason for IPO
|
For construction of expansion project of Orion Pharma
Limited at Valuka, Mymensingh in terms of the
expansion of the existing product line along with the
addition of new product lines.
|
|
Subscription open
|
06 Jan 2013
|
|
Subscription close
|
10 Jan 2013
|
|
Subscription close for NRB
|
06 Jan 2013
to 19 Jan 2013
|
|
Offer price
|
Tk. 60.0
|
|
Face value per share
|
Tk. 10.0
|
|
Market lot
|
100 units
|
|
Single lot price
|
Tk. 6000.0
|
|
EPS
|
Tk. 5.57 for the year ended December 31, 2011.
|
|
NAV
|
Tk. 76.87 (considering revaluation reserve) as on
December 31, 2011.
Tk. 61.43 (without revaluation reserve) as on December
31, 2011.
|
|
Public offer
|
40,000,000
|
|
Major product
|
Enliven (Imatinib Mesylate) capsule, Betacal (Atenolol
plus amlodipine) tab, Vertex injection (Ceftriaxone
sodium), Clognil plus (Clopidogrel+ Aspirin) tab, Pep
(Zinc sulphate) Tab/Syrup, Deslor (Desloratadine)
Tab/Syp, Axet (Cefuroxime) Tab/inj, Pedicef
(Cefpodoxime) susp, Azalid (Azithromycin) Tab/Sus,
Truso (Cefixime) Cap/sus.
|
|
Issue Manager
|
ICB Capital Management Limited
|
|
Website
|
www.orion-group.net
|
